Innate PharmaIPHA -0.05%41 Pretax Margin % is -2,493.57% as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 947 Biotechnology companies, Innate Pharma ranks worse than 83.1% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Innate Pharma's Pre-Tax Income for the
six
months ended in Dec. 2025 was $-32.59 Mil. Innate Pharma's Revenue for the
six
months ended in Dec. 2025 was $1.31 Mil. Therefore, Innate Pharma's pretax margin for the quarter that ended in Dec. 2025 was -2,493.57%.
The historical rank and industry rank for Innate Pharma's Pretax Margin % or its related term are showing as below:
IPHA'
s Pretax Margin % Range Over the Past 10 Years
Min: -1764.51 Med: -65.76 Max: 23.04
Current: -1764.51
IPHA's Pretax Margin % is ranked worse than 83.1% of 947
companies
in the Biotechnology industry
Industry Median: -92.22
vs IPHA: -1764.51
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Innate Pharma Pretax Margin % Related Terms
Innate Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Innate Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Pretax Margin % of -2,493.57% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #787 out of 947 companies in the Biotechnology industry, placing it in the top 83.1%.
Is Innate Pharma's Pretax Margin % too high?
Innate Pharma's current Pretax Margin % is -2,493.57%. Based on the distribution chart, Innate Pharma ranks #787 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #787 out of 947 companies for Pretax Margin %. This places Innate Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Innate Pharma and its competitors. Innate Pharma's current Pretax Margin % is -2,493.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1086.9% above its estimated fair value. The current Pretax Margin % is -2,493.57%. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Pretax Margin % is -2,493.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.90 is trading 1086.9% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Pretax Margin %: -2,493.57%
GF Value™: $0.16 vs. price of $1.90 (1086.9% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
